nodes	percent_of_prediction	percent_of_DWPC	metapath
Ciclesonide—CYP3A4—Cytarabine—lymphatic system cancer	0.0575	0.318	CbGbCtD
Ciclesonide—CYP3A4—Teniposide—lymphatic system cancer	0.0566	0.313	CbGbCtD
Ciclesonide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0396	0.219	CbGbCtD
Ciclesonide—Tonsillitis—Mitoxantrone—lymphatic system cancer	0.0353	0.0431	CcSEcCtD
Ciclesonide—CYP3A4—Vincristine—lymphatic system cancer	0.0273	0.151	CbGbCtD
Ciclesonide—Osteoporosis—Fludarabine—lymphatic system cancer	0.0267	0.0327	CcSEcCtD
Ciclesonide—Impaired healing—Carmustine—lymphatic system cancer	0.0222	0.0271	CcSEcCtD
Ciclesonide—Obstructive airways disorder—Methotrexate—lymphatic system cancer	0.0196	0.0239	CcSEcCtD
Ciclesonide—Oral candidiasis—Carmustine—lymphatic system cancer	0.0151	0.0184	CcSEcCtD
Ciclesonide—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.0117	0.0143	CcSEcCtD
Ciclesonide—Ulcer—Bleomycin—lymphatic system cancer	0.0116	0.0142	CcSEcCtD
Ciclesonide—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.0116	0.0142	CcSEcCtD
Ciclesonide—Gamma-glutamyltransferase increased—Mitoxantrone—lymphatic system cancer	0.0108	0.0132	CcSEcCtD
Ciclesonide—Wheezing—Bleomycin—lymphatic system cancer	0.0107	0.013	CcSEcCtD
Ciclesonide—Bronchospasm—Teniposide—lymphatic system cancer	0.0105	0.0129	CcSEcCtD
Ciclesonide—Impaired healing—Methotrexate—lymphatic system cancer	0.0103	0.0125	CcSEcCtD
Ciclesonide—Contusion—Mitoxantrone—lymphatic system cancer	0.0102	0.0125	CcSEcCtD
Ciclesonide—Ulcer—Mitoxantrone—lymphatic system cancer	0.00943	0.0115	CcSEcCtD
Ciclesonide—Candida infection—Carmustine—lymphatic system cancer	0.00916	0.0112	CcSEcCtD
Ciclesonide—Bronchitis—Fludarabine—lymphatic system cancer	0.00904	0.011	CcSEcCtD
Ciclesonide—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00874	0.0107	CcSEcCtD
Ciclesonide—Haemoglobin—Teniposide—lymphatic system cancer	0.00861	0.0105	CcSEcCtD
Ciclesonide—Haemorrhage—Teniposide—lymphatic system cancer	0.00856	0.0105	CcSEcCtD
Ciclesonide—Pneumonia—Fludarabine—lymphatic system cancer	0.00843	0.0103	CcSEcCtD
Ciclesonide—Infection—Mechlorethamine—lymphatic system cancer	0.0082	0.01	CcSEcCtD
Ciclesonide—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00815	0.00995	CcSEcCtD
Ciclesonide—Diabetes mellitus—Carmustine—lymphatic system cancer	0.00801	0.00978	CcSEcCtD
Ciclesonide—Osteoporosis—Methotrexate—lymphatic system cancer	0.00793	0.00968	CcSEcCtD
Ciclesonide—Epistaxis—Fludarabine—lymphatic system cancer	0.00791	0.00966	CcSEcCtD
Ciclesonide—Swelling—Carmustine—lymphatic system cancer	0.00789	0.00964	CcSEcCtD
Ciclesonide—Sinusitis—Fludarabine—lymphatic system cancer	0.00787	0.00961	CcSEcCtD
Ciclesonide—Multiple fractures—Methotrexate—lymphatic system cancer	0.00765	0.00934	CcSEcCtD
Ciclesonide—Fracture—Methotrexate—lymphatic system cancer	0.00765	0.00934	CcSEcCtD
Ciclesonide—Haemoglobin—Fludarabine—lymphatic system cancer	0.00757	0.00924	CcSEcCtD
Ciclesonide—Haemorrhage—Fludarabine—lymphatic system cancer	0.00753	0.00919	CcSEcCtD
Ciclesonide—Pharyngitis—Fludarabine—lymphatic system cancer	0.00747	0.00912	CcSEcCtD
Ciclesonide—Swelling—Mitoxantrone—lymphatic system cancer	0.00734	0.00896	CcSEcCtD
Ciclesonide—Bronchospasm—Bleomycin—lymphatic system cancer	0.00678	0.00828	CcSEcCtD
Ciclesonide—Face oedema—Carmustine—lymphatic system cancer	0.00672	0.00821	CcSEcCtD
Ciclesonide—Pain in extremity—Vincristine—lymphatic system cancer	0.00665	0.00812	CcSEcCtD
Ciclesonide—Hypertension—Teniposide—lymphatic system cancer	0.00644	0.00786	CcSEcCtD
Ciclesonide—Chest pain—Teniposide—lymphatic system cancer	0.00635	0.00775	CcSEcCtD
Ciclesonide—Pneumonia—Bleomycin—lymphatic system cancer	0.00618	0.00755	CcSEcCtD
Ciclesonide—Infection—Teniposide—lymphatic system cancer	0.00604	0.00738	CcSEcCtD
Ciclesonide—Cough—Fludarabine—lymphatic system cancer	0.00572	0.00698	CcSEcCtD
Ciclesonide—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00571	0.00697	CcSEcCtD
Ciclesonide—Arthralgia—Fludarabine—lymphatic system cancer	0.00558	0.00681	CcSEcCtD
Ciclesonide—Haemoglobin—Bleomycin—lymphatic system cancer	0.00555	0.00677	CcSEcCtD
Ciclesonide—Haemorrhage—Bleomycin—lymphatic system cancer	0.00552	0.00674	CcSEcCtD
Ciclesonide—Dyspnoea—Teniposide—lymphatic system cancer	0.00542	0.00662	CcSEcCtD
Ciclesonide—Pneumonia—Carmustine—lymphatic system cancer	0.0054	0.00659	CcSEcCtD
Ciclesonide—Infection—Fludarabine—lymphatic system cancer	0.00531	0.00649	CcSEcCtD
Ciclesonide—Urinary tract infection—Carmustine—lymphatic system cancer	0.00522	0.00637	CcSEcCtD
Ciclesonide—Rash—Mechlorethamine—lymphatic system cancer	0.0052	0.00635	CcSEcCtD
Ciclesonide—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.0052	0.00635	CcSEcCtD
Ciclesonide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0052	0.00635	CcSEcCtD
Ciclesonide—Pneumonia—Vincristine—lymphatic system cancer	0.00515	0.00629	CcSEcCtD
Ciclesonide—Weight increased—Mitoxantrone—lymphatic system cancer	0.00509	0.00622	CcSEcCtD
Ciclesonide—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00502	0.00613	CcSEcCtD
Ciclesonide—Nausea—Mechlorethamine—lymphatic system cancer	0.0049	0.00599	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00487	0.00595	CcSEcCtD
Ciclesonide—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00485	0.00592	CcSEcCtD
Ciclesonide—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00485	0.00592	CcSEcCtD
Ciclesonide—Haemoglobin—Carmustine—lymphatic system cancer	0.00484	0.00591	CcSEcCtD
Ciclesonide—Urticaria—Teniposide—lymphatic system cancer	0.00483	0.0059	CcSEcCtD
Ciclesonide—Haemorrhage—Carmustine—lymphatic system cancer	0.00482	0.00588	CcSEcCtD
Ciclesonide—Dyspnoea—Fludarabine—lymphatic system cancer	0.00477	0.00582	CcSEcCtD
Ciclesonide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00471	0.00575	CcSEcCtD
Ciclesonide—Ulcer—Methotrexate—lymphatic system cancer	0.0047	0.00574	CcSEcCtD
Ciclesonide—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00468	0.00572	CcSEcCtD
Ciclesonide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00462	0.00564	CcSEcCtD
Ciclesonide—Fatigue—Fludarabine—lymphatic system cancer	0.00461	0.00563	CcSEcCtD
Ciclesonide—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.0045	0.0055	CcSEcCtD
Ciclesonide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00449	0.00548	CcSEcCtD
Ciclesonide—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00448	0.00547	CcSEcCtD
Ciclesonide—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00444	0.00543	CcSEcCtD
Ciclesonide—Asthenia—Teniposide—lymphatic system cancer	0.00437	0.00533	CcSEcCtD
Ciclesonide—Cough—Bleomycin—lymphatic system cancer	0.00419	0.00512	CcSEcCtD
Ciclesonide—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00414	0.00506	CcSEcCtD
Ciclesonide—Chest pain—Bleomycin—lymphatic system cancer	0.00409	0.00499	CcSEcCtD
Ciclesonide—Back pain—Carmustine—lymphatic system cancer	0.00406	0.00495	CcSEcCtD
Ciclesonide—Infection—Bleomycin—lymphatic system cancer	0.0039	0.00476	CcSEcCtD
Ciclesonide—Back pain—Vincristine—lymphatic system cancer	0.00387	0.00473	CcSEcCtD
Ciclesonide—Asthenia—Fludarabine—lymphatic system cancer	0.00384	0.00469	CcSEcCtD
Ciclesonide—Rash—Teniposide—lymphatic system cancer	0.00384	0.00468	CcSEcCtD
Ciclesonide—Dermatitis—Teniposide—lymphatic system cancer	0.00383	0.00468	CcSEcCtD
Ciclesonide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00382	0.00466	CcSEcCtD
Ciclesonide—Headache—Teniposide—lymphatic system cancer	0.00381	0.00465	CcSEcCtD
Ciclesonide—Back pain—Mitoxantrone—lymphatic system cancer	0.00377	0.0046	CcSEcCtD
Ciclesonide—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00371	0.00453	CcSEcCtD
Ciclesonide—Hypertension—Carmustine—lymphatic system cancer	0.00362	0.00442	CcSEcCtD
Ciclesonide—Nausea—Teniposide—lymphatic system cancer	0.00361	0.00441	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00357	0.00436	CcSEcCtD
Ciclesonide—Chest pain—Carmustine—lymphatic system cancer	0.00357	0.00436	CcSEcCtD
Ciclesonide—Dyspnoea—Bleomycin—lymphatic system cancer	0.0035	0.00427	CcSEcCtD
Ciclesonide—Hypertension—Vincristine—lymphatic system cancer	0.00346	0.00422	CcSEcCtD
Ciclesonide—Cough—Mitoxantrone—lymphatic system cancer	0.0034	0.00415	CcSEcCtD
Ciclesonide—Infection—Carmustine—lymphatic system cancer	0.0034	0.00415	CcSEcCtD
Ciclesonide—Rash—Fludarabine—lymphatic system cancer	0.00337	0.00412	CcSEcCtD
Ciclesonide—Dermatitis—Fludarabine—lymphatic system cancer	0.00337	0.00411	CcSEcCtD
Ciclesonide—Hypertension—Mitoxantrone—lymphatic system cancer	0.00337	0.00411	CcSEcCtD
Ciclesonide—Headache—Fludarabine—lymphatic system cancer	0.00335	0.00409	CcSEcCtD
Ciclesonide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00332	0.00405	CcSEcCtD
Ciclesonide—Chest pain—Mitoxantrone—lymphatic system cancer	0.00332	0.00405	CcSEcCtD
Ciclesonide—Infection—Vincristine—lymphatic system cancer	0.00325	0.00396	CcSEcCtD
Ciclesonide—Nausea—Fludarabine—lymphatic system cancer	0.00318	0.00388	CcSEcCtD
Ciclesonide—Infection—Mitoxantrone—lymphatic system cancer	0.00316	0.00386	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00312	0.00381	CcSEcCtD
Ciclesonide—Urticaria—Bleomycin—lymphatic system cancer	0.00311	0.0038	CcSEcCtD
Ciclesonide—Dyspnoea—Carmustine—lymphatic system cancer	0.00305	0.00373	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00298	0.00363	CcSEcCtD
Ciclesonide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00295	0.00361	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.0029	0.00354	CcSEcCtD
Ciclesonide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00284	0.00346	CcSEcCtD
Ciclesonide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00282	0.00344	CcSEcCtD
Ciclesonide—Fatigue—Vincristine—lymphatic system cancer	0.00282	0.00344	CcSEcCtD
Ciclesonide—Asthenia—Bleomycin—lymphatic system cancer	0.00281	0.00344	CcSEcCtD
Ciclesonide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.0028	0.00342	CcSEcCtD
Ciclesonide—Fatigue—Mitoxantrone—lymphatic system cancer	0.00274	0.00335	CcSEcCtD
Ciclesonide—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00259	0.00316	CcSEcCtD
Ciclesonide—Urticaria—Mitoxantrone—lymphatic system cancer	0.00253	0.00309	CcSEcCtD
Ciclesonide—Pneumonia—Methotrexate—lymphatic system cancer	0.0025	0.00305	CcSEcCtD
Ciclesonide—Infestation—Methotrexate—lymphatic system cancer	0.00249	0.00304	CcSEcCtD
Ciclesonide—Infestation NOS—Methotrexate—lymphatic system cancer	0.00249	0.00304	CcSEcCtD
Ciclesonide—Rash—Bleomycin—lymphatic system cancer	0.00247	0.00302	CcSEcCtD
Ciclesonide—Dermatitis—Bleomycin—lymphatic system cancer	0.00247	0.00302	CcSEcCtD
Ciclesonide—Asthenia—Carmustine—lymphatic system cancer	0.00246	0.003	CcSEcCtD
Ciclesonide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00242	0.00295	CcSEcCtD
Ciclesonide—Epistaxis—Methotrexate—lymphatic system cancer	0.00234	0.00286	CcSEcCtD
Ciclesonide—Asthenia—Vincristine—lymphatic system cancer	0.00234	0.00286	CcSEcCtD
Ciclesonide—Nausea—Bleomycin—lymphatic system cancer	0.00233	0.00284	CcSEcCtD
Ciclesonide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00228	0.00279	CcSEcCtD
Ciclesonide—Dizziness—Carmustine—lymphatic system cancer	0.00226	0.00276	CcSEcCtD
Ciclesonide—Haemoglobin—Methotrexate—lymphatic system cancer	0.00224	0.00274	CcSEcCtD
Ciclesonide—Haemorrhage—Methotrexate—lymphatic system cancer	0.00223	0.00272	CcSEcCtD
Ciclesonide—Pharyngitis—Methotrexate—lymphatic system cancer	0.00221	0.0027	CcSEcCtD
Ciclesonide—Dizziness—Vincristine—lymphatic system cancer	0.00216	0.00264	CcSEcCtD
Ciclesonide—Rash—Carmustine—lymphatic system cancer	0.00216	0.00264	CcSEcCtD
Ciclesonide—Dermatitis—Carmustine—lymphatic system cancer	0.00216	0.00263	CcSEcCtD
Ciclesonide—Headache—Carmustine—lymphatic system cancer	0.00214	0.00262	CcSEcCtD
Ciclesonide—Rash—Vincristine—lymphatic system cancer	0.00206	0.00252	CcSEcCtD
Ciclesonide—Dermatitis—Vincristine—lymphatic system cancer	0.00206	0.00251	CcSEcCtD
Ciclesonide—Headache—Vincristine—lymphatic system cancer	0.00205	0.0025	CcSEcCtD
Ciclesonide—Nausea—Carmustine—lymphatic system cancer	0.00203	0.00248	CcSEcCtD
Ciclesonide—Immune system disorder—Methotrexate—lymphatic system cancer	0.00202	0.00246	CcSEcCtD
Ciclesonide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00201	0.00246	CcSEcCtD
Ciclesonide—Rash—Mitoxantrone—lymphatic system cancer	0.00201	0.00245	CcSEcCtD
Ciclesonide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.002	0.00245	CcSEcCtD
Ciclesonide—Headache—Mitoxantrone—lymphatic system cancer	0.00199	0.00243	CcSEcCtD
Ciclesonide—Nausea—Vincristine—lymphatic system cancer	0.00194	0.00237	CcSEcCtD
Ciclesonide—Dysgeusia—Methotrexate—lymphatic system cancer	0.0019	0.00232	CcSEcCtD
Ciclesonide—Nausea—Mitoxantrone—lymphatic system cancer	0.00189	0.00231	CcSEcCtD
Ciclesonide—Back pain—Methotrexate—lymphatic system cancer	0.00188	0.00229	CcSEcCtD
Ciclesonide—Cough—Methotrexate—lymphatic system cancer	0.0017	0.00207	CcSEcCtD
Ciclesonide—Chest pain—Methotrexate—lymphatic system cancer	0.00165	0.00202	CcSEcCtD
Ciclesonide—Arthralgia—Methotrexate—lymphatic system cancer	0.00165	0.00202	CcSEcCtD
Ciclesonide—Infection—Methotrexate—lymphatic system cancer	0.00157	0.00192	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00144	0.00176	CcSEcCtD
Ciclesonide—Dyspnoea—Methotrexate—lymphatic system cancer	0.00141	0.00173	CcSEcCtD
Ciclesonide—Dyspepsia—Methotrexate—lymphatic system cancer	0.0014	0.0017	CcSEcCtD
Ciclesonide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00137	0.00167	CcSEcCtD
Ciclesonide—Fatigue—Methotrexate—lymphatic system cancer	0.00137	0.00167	CcSEcCtD
Ciclesonide—Urticaria—Methotrexate—lymphatic system cancer	0.00126	0.00154	CcSEcCtD
Ciclesonide—Asthenia—Methotrexate—lymphatic system cancer	0.00114	0.00139	CcSEcCtD
Ciclesonide—Dizziness—Methotrexate—lymphatic system cancer	0.00105	0.00128	CcSEcCtD
Ciclesonide—Rash—Methotrexate—lymphatic system cancer	0.001	0.00122	CcSEcCtD
Ciclesonide—Dermatitis—Methotrexate—lymphatic system cancer	0.000999	0.00122	CcSEcCtD
Ciclesonide—Headache—Methotrexate—lymphatic system cancer	0.000993	0.00121	CcSEcCtD
Ciclesonide—Nausea—Methotrexate—lymphatic system cancer	0.000942	0.00115	CcSEcCtD
